Which of the following is a first-line drug for the treatment of active tuberculosis?

Choice A reason: Combining heparin and warfarin does not reduce adverse effects. Heparin risks bleeding and thrombocytopenia, while warfarin adds bleeding risk. The combination is used to bridge therapy until warfarin’s anticoagulant effect is therapeutic, not to minimize side effects, making this statement incorrect.

Choice B reason: Heparin provides immediate anticoagulation by enhancing antithrombin activity, inhibiting thrombin and factor Xa. Warfarin takes 3-5 days to achieve therapeutic INR by inhibiting vitamin K-dependent clotting factors. Heparin bridges this delay, ensuring continuous anticoagulation during warfarin initiation, making this the correct response.

Choice C reason: Heparin and warfarin do not work synergistically. Heparin acts rapidly via antithrombin, while warfarin slowly inhibits clotting factor synthesis. Their effects are independent, used together to maintain anticoagulation during warfarin’s delayed onset, not to enhance each other’s mechanisms, making this inaccurate.

Choice D reason: Warfarin is not used because heparin is insufficient but to provide long-term oral anticoagulation. Heparin is effective but requires IV administration, while warfarin allows outpatient management. The combination ensures anticoagulation during warfarin’s onset, not to compensate for heparin’s inadequacy.

Choice A reason: Carbapenems, like imipenem, are broad-spectrum antibiotics reserved for severe, multidrug-resistant infections. They are not first-line for uncomplicated urinary tract infections due to their potency and risk of promoting resistance. Sulfonamides are more commonly used for UTIs due to their efficacy and specificity.

Choice B reason: Sulfonamides, like trimethoprim-sulfamethoxazole, are especially useful for urinary tract infections. They inhibit bacterial folate synthesis, targeting pathogens like Escherichia coli, a common UTI cause. Their concentration in urine enhances efficacy, making them a first-line choice for uncomplicated UTIs in susceptible organisms.

Choice C reason: Tetracyclines, like doxycycline, are not typically used for urinary tract infections. They are effective for other infections, like chlamydia, but their spectrum and renal clearance make them less ideal for common UTI pathogens like E. coli compared to sulfonamides or nitrofurantoin.

Choice D reason: Macrolides, like erythromycin, are used for respiratory or soft tissue infections, not primarily for urinary tract infections. They have limited activity against common UTI pathogens like E. coli and do not concentrate effectively in urine, making sulfonamides a more appropriate choice.